Silence Therapeutics plc Investing Cash Flow
Silence Therapeutics plc (SLN) reported Investing Cash Flow of $74.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Silence Therapeutics plc net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $64.94M.
- Silence Therapeutics plc net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $10.00M.
- Silence Therapeutics plc net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$53.34M, a 180.66% decline year-over-year.
- Silence Therapeutics plc net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $51.29M.
- Silence Therapeutics plc net cash provided by (used in) investing activities for fiscal 2025 was -$47.99M.
- Silence Therapeutics plc net cash provided by (used in) investing activities for fiscal 2024 was -$21.97M, a 213.85% decline from fiscal 2023.
- Silence Therapeutics plc net cash provided by (used in) investing activities for fiscal 2023 was $19.29M.
- Silence Therapeutics plc net cash provided by (used in) investing activities for fiscal 2022 was -$20.50M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $64.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $74.94M 10-Q · filed 2026-08-10 | $21.60M derived: sum of 3 quarters · filed 2026-08-10 | $72.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-07 | -$43.34M derived: sum of 2 quarters · filed 2026-05-07 | $7.95M derived: sum of 3 quarters · filed 2026-05-07 | $6.39M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$53.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.05M derived: sum of 2 quarters · filed 2026-03-05 | -$3.61M derived: sum of 3 quarters · filed 2026-08-10 | -$47.99M 10-K · filed 2026-03-05 |
| 2025-09-30 | $51.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.73M derived: sum of 2 quarters · filed 2026-08-10 | $5.35M 10-Q · filed 2025-11-06 | $71.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$45.94M 10-Q · filed 2026-08-10 | $20.18M derived: sum of 3 quarters · filed 2026-08-10 | -$17.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$44.38M 10-Q · filed 2026-05-07 | $21.74M derived: sum of 2 quarters · filed 2026-05-07 | -$16.40M derived: sum of 3 quarters · filed 2026-05-07 | -$16.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $66.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $27.98M derived: sum of 2 quarters · filed 2026-03-05 | $27.94M derived: sum of 3 quarters · filed 2026-03-05 | -$21.97M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$38.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$38.18M derived: sum of 2 quarters · filed 2025-11-06 | -$88.09M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$49.95M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$49.91M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $19.29M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | -$20.50M 10-K · filed 2025-02-27 |